Billing and Coding: MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma

This billing and coding guidance requires reporting molecular assays for cutaneous melanoma with appropriate CPT/PLA codes (CPT 81479 or proprietary 0090U for myPath®Melanoma after 2019-07-01). Only one test (one unit of service) may be billed per patient per melanocytic lesion, and the appropriate DEX Z-Code identifier and ICD-10-CM diagnosis code must be included in the specified electronic or paper claim fields.

"Molecular assays used for the diagnosis of cutaneous melanoma (melanocytic lesions) may be billed when appropriate CPT or PLA codes are reported."

Sign up to see full coverage criteria, indications, and limitations.